In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers.
Ardeshirpour, Yasaman; Chernomordik, Victor; Zielinski, Rafal; Capala, Jacek; Griffiths, Gary; Vasalatiy, Olga; Smirnov, Aleksandr V; Knutson, Jay R; Lyakhov, Ilya; Achilefu, Samuel; Gandjbakhche, Amir; Hassan, Moinuddin.
; 7(2): e31881, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22384092
Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: New biology and novel targeting systems.
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.
Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH.
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.
A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Targeting HER2 in Nuclear Medicine for Imaging and Therapy.
Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs.
Structural basis for high-affinity HER2 receptor binding by an engineered protein.